High materiality8/10
Stifel Reiterates Buy Rating on Contineum Therapeutics (CTNM)
Why it may matterVerify against the original reporting
very_bullish
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Stifel Nicolaus reiterates Buy rating on CTNM; target $28; current price $12.92; price change +0.29 since signal.
- CTNM: Buy rating reiterated; target $28; price $12.92.
- Stifel upgrades CTNM upside.
Key facts
- 01
Target: $28
- 02
Posted price: $12.92
- 03
Analyst firm: Stifel Nicolaus
- 04
Analyst: Paul Matteis
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.